Infectious Disease Topics
RSSArticles
-
Infectious Disease Alert Updates
Let’s Not Shake on This; The Tricky Business of Treating Early Cocci; On-Site Rapid Detection of Bacteriuria
-
Ceftriaxone-Resistant Salmonella Typhi in the United States Associated with Travel to or from Pakistan and Iraq
Typhoid fever resulting from antibiotic-resistant strains is being imported from Pakistan and Iraq.
-
IDSA Sepsis Committee and SEP-1 Quality Measures
The IDSA Sepsis Committee proposes that The Centers for Medicare & Medicaid Services’ Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) should be applied only to septic shock, not sepsis without shock.
-
Contact Isolation Is Not Better than Standard Precautions for Decreasing Acquisition of ESBL-Producing Enterobacterales
In a multicenter, cluster-randomized crossover trial, researchers compared standard precautions vs. contact isolation for preventing acquisition of ESBL-producing Enterobacterales (ESBL-E) in non-intensive care unit settings. Contact isolation did not decrease the number of hospital-acquired ESBL-E cases, which questions the value of the practice.
-
Monotherapy of Pseudomonas aeruginosa Bacteremia — Which β-Lactam Antibiotic Is Best?
No significant difference in the mortality of patients with Pseudomonas aeruginosa bacteremia was seen regardless of treatment with a carbapenem, ceftazidime, or piperacillin-tazobactam. However, the emergence of resistance occurred significantly more frequently in those treated with a carbapenem — largely related to imipenem use.
-
Macrolides During Pregnancy — Behind the Headlines
Despite published concerns, there is no good evidence that macrolide use during pregnancy causes birth defects.
-
Remdesivir and COVID-19
Remdesivir is safe and moderately effective in the treatment of patients with COVID-19.
-
Infectious Disease Alert Updates
Complications of Typhoid Fever; Do I Smell a Rat? Or Is the Rat Smelling Me? Cloth Masks — Just for Looks?
-
Lefamulin: Formulary Considerations
The Food and Drug Administration (FDA) recently approved lefamulin for the treatment of adults with community-acquired bacterial pneumonia (CABP).
-
Antibiotic Therapy to Reduce the Incidence of Ventilator-Associated Pneumonia After Cardiac Arrest
In this prospective, randomized trial, intravenous amoxicillin-clavulanate (dosed three times daily and given for two days) administered to patients admitted with out-of-hospital cardiac arrest due to a shockable rhythm reduced the incidence of early ventilator-associated pneumonia.